Women's Health

Individuals who identified as a sexual minority had lower odds of ever undergoing Pap testing compared with heterosexual individuals, according to a study published in Cancer.

HD201, a trastuzumab biosimilar candidate, demonstrated equivalent efficacy to referent trastuzumab among patients with ERBB2-positive early breast cancer, according to phase 3 study results published in JAMA Oncology.

Each year, National Women’s Health Week emphasizes how important it is for women to prioritize their health.

A decrease in cervical cancer rates in the United States, most notably among younger women, may be associated with HPV vaccination approval, according to a retrospective, cross-sectional study published in JAMA Network Open.

SAN DIEGO — Several abstracts were presented at the ACOG Annual Clinical & Scientific Meeting on the efficacy and safety of linzagolix, an investigational oral GnRH antagonist being developed for the treatment of fibroid-related symptoms.

SAN DIEGO — In this video, Cynthia Gyamfi-Bannerman, MD, MS, FACOG, discusses the impact of SARS-CoV-2 on the pregnant population, which was the focus of her presentation at the ACOG Annual Clinical & Scientific Meeting.

Women who initiated endoscopy screening before age 50 years demonstrated a significantly reduced risk for colorectal cancer than women who did not undergo endoscopy, according to study results published in JAMA Oncology.

After 2 consecutive years of virtual conferences, ACOG is back to hosting its Annual Clinical & Scientific Meeting in person.

The addition of ribociclib to fulvestrant conferred a survival benefit of nearly 16 months as first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, topline data showed.

The FDA granted fast track designation to ofranergene obadenovec in combination with paclitaxel for treatment of platinum-resistant ovarian cancer.